These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 7489961)

  • 1. Efficacy and safety of a monoclonal purified factor VIII concentrate: 5-year follow-up in previously treated HIV-negative haemophiliacs.
    Smid WM; van der Meer J; Halie MR
    Haemostasis; 1995; 25(5):229-36. PubMed ID: 7489961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The course of preexistent immune abnormalities in HIV negative haemophiliacs treated for two years with a monoclonal purified factor VIII concentrate.
    Smid WM; van der Meer J; Smit JW; Halie MR
    Thromb Haemost; 1993 Apr; 69(4):306-10. PubMed ID: 8388579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of chronic factor VIII substitution on immune parameters in HIV seronegative haemophiliacs: a comparison between cryoprecipitate and factor VIII concentrate.
    Allersma DP; Smid WM; van der Does JA; van der Meer J; Briët E
    Thromb Haemost; 1996 Feb; 75(2):261-6. PubMed ID: 8815573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.
    Mauser-Bunschoten EP; Posthouwer D; Fischer K; van den Berg HM
    Haemophilia; 2007 Nov; 13(6):697-700. PubMed ID: 17877729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of monoclonal or ion-exchange purified factor VIII concentrate on HIV disease progression: a prospective cohort comparison.
    Hay CR; Ludlam CA; Lowe GD; Mayne EE; Lee RJ; Prescott RJ; Lee CA
    Br J Haematol; 1998 Jun; 101(4):632-7. PubMed ID: 9674733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble interleukin 2 receptor and soluble CD8 levels in previously treated human immunodeficiency virus-negative hemophiliacs multiply transfused with a monoclonal antibody-purified factor VIII concentrate.
    Smid WM; Martens A; van der Meer J; Hegge-Paping CS; Halie MR
    Transfusion; 1997 Jan; 37(1):86-9. PubMed ID: 9024495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High versus ultra-high purity factor VIII concentrate therapy: prospective evaluation of immunological and clinical parameters in HIV seronegative and seropositive hemophiliacs.
    Varon D; Schulman S; Dardik R; Barzilai A; Bashari D; Martinowitz U
    Thromb Haemost; 1994 Sep; 72(3):359-62. PubMed ID: 7855784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor VIII:C concentrate purified from plasma using monoclonal antibodies: human studies.
    Brettler DB; Forsberg AD; Levine PH; Petillo J; Lamon K; Sullivan JL
    Blood; 1989 May; 73(7):1859-63. PubMed ID: 2496775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4+ counts before and after switching to monoclonal high-purity factor VIII concentrate in HIV-infected haemophilic patients.
    Sabin C; Pasi J; Phillips A; Elford J; Janossy G; Lee C
    Thromb Haemost; 1994 Aug; 72(2):214-7. PubMed ID: 7831654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-year follow-up of human anti-mouse antibody in multitransfused HIV negative haemophilics treated with a monoclonal purified plasma derived factor VIII concentrate.
    Smid WM; van der Meer J
    Thromb Haemost; 1995 Oct; 74(4):1203. PubMed ID: 8560440
    [No Abstract]   [Full Text] [Related]  

  • 11. Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status.
    Seremetis SV; Aledort LM; Bergman GE; Bona R; Bray G; Brettler D; Eyster ME; Kessler C; Lau TS; Lusher J
    Lancet; 1993 Sep; 342(8873):700-3. PubMed ID: 8103820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of immunodeficiency and AIDS defining conditions in HIV negative and HIV positive men with haemophilia A.
    Sabin CA; Pasi KJ; Phillips AN; Lilley P; Bofill M; Lee CA
    BMJ; 1996 Jan; 312(7025):207-10. PubMed ID: 8563582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Outcome of hemorrhage treatment in children with hemophilia A related to factor VIII inhibitor].
    Klukowska A; Zieleniewska B
    Acta Haematol Pol; 1994; 25(4):349-54. PubMed ID: 7847036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal purified F VIII for continuous infusion: stability, microbiological safety and clinical experience.
    Schulman S; Varon D; Keller N; Gitel S; Martinowitz U
    Thromb Haemost; 1994 Sep; 72(3):403-7. PubMed ID: 7855792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective clinical trial of high-purity factor VIII preparations in haemophiliacs.
    Varon D
    Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S82-3. PubMed ID: 7495975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A.
    Hsu HC; Chen YF; Ho CH
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jul; 62(7):450-4. PubMed ID: 10418180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zero incidence of inhibitor development in previously treated haemophilia A, HIV-negative patients upon exposure to a plasma-derived high-purity and double viral inactivated factor VIII concentrate.
    Aznar JA; Lorenzo JI; Molina R; Haya S; Querol F; Dasí MA
    Haemophilia; 1998 Jan; 4(1):21-4. PubMed ID: 9873861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Purity of factor VIII concentrates and serial CD4 counts. The Transfusion Safety Study Group.
    Hilgartner MW; Buckley JD; Operskalski EA; Pike MC; Mosley JW
    Lancet; 1993 May; 341(8857):1373-4. PubMed ID: 8098792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical testing of Premofil M SRK, a blood coagulation factor VIII concentrate purified from human plasma using monoclonal an antibodies].
    Perret BA; Poorbeik M; Morell A
    Schweiz Med Wochenschr; 1991 Nov; 121(44):1624-7. PubMed ID: 1947960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High purity factor VIII concentrates for the treatment of HIV-positive patients with haemophilia.
    Sultan Y
    Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S80-1. PubMed ID: 7495974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.